3 Online Payment Stocks Capitalizing On Covid-Era Trends. 3 Consumer Defensive Stocks Delivering Tech-Like Returns. 3 Dividend Stocks to Help You Fight Inflation.
‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 
The Early Bird Newsletter

Wednesday, April 14th

S and P pricesDow pricesQQQ prices
Good Morning

U.S. stock markets were relatively calm again on Tuesday as traders gear up for the Q1 earnings onslaught. The S&P 500 was able to edge higher but by less than half a percent to set a new all-time high. The market is being led higher by the analyst’s sentiment and a rising consensus for Q1 results. The risk for the market is that with the S&P 500 so highly valued there is a risk Q1 earnings could turn into a sell-the-news event.

Trading could take on a different tone after today. Between expected earnings reports from the big banks and economic data in the form of the Fed’s Beige Book, there is a lot of risk for the market. Among those reporting are J.P. Morgan, Goldman Sachs, and Wells Fargo. As for the Beige Book, the market will be watching it closely for any signs of rising inflation and there are sure to be some.


3 Online Payment Stocks Capitalizing On Covid-Era Trends

Back in March 2020, when lockdowns began and businesses were shut down, investors lost confidence in everything, even online payment systems such as PayPal (NASDAQ: PYPL), Square (NYSE: SQ) and Shift4 (NYSE: FOUR). 

Read The Full Story >>
From Our Partners

These 4 Cryptos Are Screaming Buys With 10X Potential

The Awakening is starting right now. Find out why PayPal just joined the wealth-creating tsunami that is about to surge through the economy in 2021. The last time such a major market event happened, it minted 18,000 new millionaires.

Here's the story.

3 Consumer Defensive Stocks Delivering Tech-Like Returns

In the world of professional sports, defense often wins championships. In stock investing, defensive companies typically don't produce championship caliber returns.Here are three of those so-called defensive names that are up big this year—and may still be in the early innings of a bigger rally.

Read The Full Story >>

3 Dividend Stocks to Help You Fight Inflation

Dividend stocks can be a great way to hedge against inflation, especially if you choose companies that are known to increase their payouts over time. Let’s take a look at 3 dividend stocks to help you fight inflation below.

Read The Full Story >>
From Our Partners

(ALERT) Google just poured $4 billion into THIS...

Companies all over the world are funneling as much money as they can into what Bill Gates calls, "the holy grail" of modern technology.

It's fresh out of a highly secretive lab in Boston, and it's poised to make early investors billions.

It's NOT bitcoin, or some other blockchain-related technology and it's NOT 5G. It's NOT cannabis.

Click here to get the details in this free briefing.

The Latest: Poland plans to use newly arrived J&J vaccines

WARSAW, Poland – Poland plans to go ahead with immunizations using the Johnson & Johnson vaccine after receiving its first batch of 120,000 doses on Wednesday. Health Minister Adam Niedzielski said Poland is following the latest recommendations from the European Medicines Agency, ...

Read The Full Story >>

10 Magic Questions That Will Help You Get To Know Your Target Audience

The following excerpt is from Dan S. Kennedy and Dustin Mathews' book No BS Guide to Powerful Presentations. Buy it now from Amazon | Barnes & Noble | iTunes or click here to buy it directly from us and SAVE 60% on this book when you use code CAREER2021 through 4...

Read The Full Story >>
From Our Partners

The Tobacco Industry Change is Here!

big tobacco executives have shied away from the product and are turning to this stock!

Continue Reading

3 Truths and 1 Lie About SPACs

As companies seek alternatives to the often lengthy IPO process, SPACs have skyrocketed in popularity. Their speed and flexible options make them attractive to entrepreneurs, while their potential for appreciation at a time when the universe of public companies has halved has draw...

Read The Full Story >>

The Benefits of Using Multiple Domains for Your Business

You already know that choosing a domain is important. In fact, it’s one of the most important early decisions you’ll make for your business. Choosing the right domain can impact your visibility, your memorability and even your reputation. It’s going to ...

Read The Full Story >>

Why You Need to Start Dating Jobs

The following excerpt is from Kanika Tolver’s book Career Rehab. Buy it now from Amazon | Barnes & Noble | iTunes or click here to buy it directly from us and SAVE 60% on this book when you use code CAREER2021 through 4/17/21.One way to...

Read The Full Story >>

Insteel Industries Stock is a U.S. Infrastructure Pure Play

The nation’s largest manufacturer of steel wire reinforcing products for concrete construction applications Insteel Industries (NYSE: IIIN) stock has been a pandemic benefactor thanks to the housing boom.

Read The Full Story >>
The Early Bird Stock Of The Day

Genmab A/S

Genmab A/S

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and BioNTech, Janssen, Novo Nordisk A/S, and BliNK Biomedical SAS. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Learn more

The Early Bird is a daily email newsletter powered by MarketBeat that covers the top stories that will impact the stock market each day. Read your copy every morning at 7:00 AM Eastern so that you can "catch the worm" when the market opens.

The Early Bird

American Consumer News, LLC dba MarketBeat
326 E 8th St #105, Sioux Falls, SD 57103
[email protected]
(844) 978-6257

Unsubscribe or Manage Your Mailing Preferences